Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | TGTX |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 6.0B |
| IPO Year | N/A | 2008 |
| Metric | AUROW | TGTX |
|---|---|---|
| Price | $0.32 | $53.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 37.2K | ★ 2.0M |
| Earning Date | 04-30-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | ★ N/A | $432.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $25.37 |
| 52 Week High | $1.08 | $53.98 |
| Indicator | AUROW | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 82.92 |
| Support Level | $0.17 | $28.57 |
| Resistance Level | $0.42 | N/A |
| Average True Range (ATR) | 0.08 | 2.43 |
| MACD | -0.02 | 1.13 |
| Stochastic Oscillator | 4.94 | 95.68 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.